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A randomised 6-month study compared two maintenance doses of budesonide/formoterol
(Symbicort Turbuhaler)h maintenance and reliever therapy (Symbicort SMART), 160/
4.5 mg 1  2 and 2  2, in 8053 asthmatics with symptoms despite treatment with inhaled
corticosteroids  inhaled long-acting b2-agonists. This analysis compared response to the
two treatments in elderly patients, 65 years, with that in younger patients. Elderly patients
with early- or late-onset asthma were also compared.
Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at base-
line than younger patients (85.6% vs. 91.0%, respectively). The elderly had more exacerbations
and risk of first severe exacerbation was increased by 55.3% (hazard ratio 1.553; 95% confi-
dence interval: 1.249e1.931, p < 0.0001). However, no differences in exacerbations were seen
between 1  2 or 2  2 budesonide/formoterol maintenance and reliever therapy treatment in
the elderly. Five-item Asthma Control Questionnaire (ACQ-5) scores improved equally in the
two age groups. Changes in mean ACQ-5 scores between 1  2 and 2  2 were significant in
both age groups but not clinically relevant (65 years, 0.12; p Z 0.018; <65 years, 0.09;
p < 0.0001). Elderly patients with early- and late-onset asthma responded equally well to
treatment.224 553972; fax: þ44 1224 550683.
ac.uk (J. Haughney).
logy nor the dry powder formulation, Turbuhaler, is currently approved in the US.
1 Elsevier Ltd. All rights reserved.
Comparing asthma treatment 839Budesonide/formoterol maintenance and reliever therapy (1  2 or 2  2) is an effective,
well-tolerated and practical treatment concept in elderly and younger asthmatic patients.
Clinical trial registration: NCT00463866
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The World Health Organization has estimated a doubling of
the world population of people over the age of 65 years
(elderly) by the year 2025.1 Asthma in the elderly is not
a rare disorder2 but may be misdiagnosed, especially as
chronic obstructive pulmonary disease (COPD).3 Approxi-
mately 50% of asthma deaths occur in the elderly.4 Under-
diagnosis has been recognised for some time5 and remains
a problem, resulting in poor treatment and impaired quality
of life of the patients.6,7 There is an increased focus on
asthma in the elderly population.8,9
Traditionally, two phenotypes of asthma have been
described in the elderly: early-onset asthma (EOA), starting
before the age of 40 years, and late-onset asthma (LOA),
starting later in life, after 40 years of age.10 In EOA, atopy is
more often detectable, whereas LOA is more often associ-
ated with respiratory tract infections, environmental
inducers or other non-allergic factors. There is some
evidence that elderly patients with EOA have poorer airway
function compared with patients with LOA, whereas
patients with LOA may show a more rapid decline over time
in forced expiratory volume in 1 s (FEV1).
11,12 Patients with
EOA also usually have less reversible airway obstruction and
poorer response to pharmacotherapy.13 Other phenotypes
have been identified and proposed in elderly asthmatics by
the cluster analysis approach.14,15
From a pathophysiological point of view, there is no
difference between asthma in the elderly and in the rest of
the population.16 What does differ between elderly and
younger patients is the pharmacokinetics of drugs due to
differences in the subjects’ volume of distribution.17
A decrease in response to interleukin-5 stimulation of
peripheral blood eosinophils in elderly has also been
reported.18
Differences reported between elderly and younger
patients relate to clinical expressions of the disease;
elderly patients are described as reporting fewer symptoms
and using less medication.19,20 Concerns have been raised
about b2-agonist response and side effects, osteoporosis
with the use of inhaled corticosteroids (ICS), exacerbations
of asthma due to medication for comorbid conditions or
technical problems with inhalation devices.19,20
Few large clinical studies have compared the results of
asthma therapies in the elderly with the rest of the asthma
population,9,10,20 reflecting the fact that elderly patients
may be excluded from controlled clinical trials.
We have previously reported the results of a large pan-
European budesonide/formoterol (Symbicort Turbuhaler)
maintenance and reliever therapy (Symbicort SMART)
study.9,21 This was an open-label, randomised 6-month study
that compared two maintenance doses of budesonide/for-
moterol 160/4.5 mg one inhalation twice daily (bid; 1  2)
and 160/4.5 mg two inhalations bid (2 2) in asthmatics over18 years. In the total study population, the time to first
severe asthma exacerbation was prolonged by 18% with
2  2 versus 1  2 (hazard ratio [HR] 0.82; p Z 0.03). Low
lung function (peak expiratory flow [PEF]) was found to be
the only statistically significant predictor of a better
response to 2  2. Among 8053 patients randomised and
analysed for the primary endpoint, 1234 (15.3%) were 65
years old. As there are few large published asthma studies in
the elderly population, we prospectively planned to perform
additional analyses on this group.
The aim of this study was to analyse the baseline char-
acteristics of the elderly subpopulation and their response
to treatment compared with the younger reference pop-
ulation. Our hypothesis was that the elderly patients may
respond less well to budesonide/formoterol maintenance
and reliever therapy than the younger reference population
and that the elderly would benefit more from the high
maintenance dose strategy (2  2) compared with the
standard maintenance treatment (1  2).
Materials and methods
Study subjects and design
Study subjects and design were as described previously.21
Male and female patients with moderate to severe asthma,
18 years old, with a minimum of 6 months documented
history of asthma according to the American Thoracic
Society definition (ATS 1987), having asthma symptoms and
a history of use of a rapid-acting b2-agonist (a short-acting
b2-agonist [SABA] or formoterol) for symptom relief during
the last month despite treatment with ICS or ICS plus a long-
acting inhaled b2-agonist (LABA) were recruited in 14 Euro-
pean countries into a 6-month open, randomised clinical
trial. Patients should have been on maintenance therapy
with ICS for at least 1 month at a constant daily dose of at
least 500 mg beclomethasone dipropionate or an equivalent
dose of any other ICS. Smokers could be enrolled; however,
smokers over 40 years of age with a smoking history of 10
pack-years or more were excluded, as were patients with
a diagnosis of COPD. There were four clinic visits in the
study: at enrolment (Visit 1), randomisation (Visit 2), after
treatment for 3 months (Visit 3) and at the end of the 6-
month study (Visit 4). Among the 8053 randomised patients
in the main EuroSMART study there were 1234 (15.3%)
patients who were 65 years of age or older.
Assessments
Demographic and clinical data were collected at baseline.
During the 2-week run-in period, and during 2-week periods
prior to Visits 3 and 4, patients recorded in a notebook the
number of inhalations taken as maintenance medication,
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during the day (yes/no) and night-time awakenings (yes/
no) due to asthma. At Visits 2 and 4, lung function assess-
ments were performed (FEV1 and PEF). PEF only was per-
formed if spirometry was not available. Patients were
instructed in the inhalation technique at Visits 1 and 2. At
Visit 2, their inhalation technique was observed by the
investigator.
Reversibility tests were performed according to local
practice and there was no demand for withholding SABA or
LABA preparations before the tests.
The five-item Asthma Control Questionnaire (ACQ-5),22e24
excluding FEV1 (as FEV1 was not measured at all clinics) and
use of SABA (as budesonide/formoterol should be used as
reliever medication) was recorded via self-administration at
Visits 2, 3 and 4. The scale of each ACQ-5 component ranges
from 0 to 6 (0 Z best, 6 Z worst). The ACQ-5 total scores
were reported in three groups: mean scores less than 0.75
(well-controlled asthma), 0.75e1.5 (intermediate group)
and greater than 1.5 (poorly controlled asthma). These
intervals were based on data from a previous large clinical
study.25 Scores were also analysed according to the threshold
for the minimal clinically meaningful difference of 0.5 score
points.
The primary efficacy variable was time to first severe
asthma exacerbation, defined as deterioration in asthma
requiring oral or systemic corticosteroids either for at least
3 days, or leading to hospitalisation, emergency room visit
or other patient-initiated unscheduled visits to a health-
care centre. Compliance with treatment was not formally
monitored as the study aimed to mimic a real-life clinical
practice. Safety was evaluated by reporting serious adverse
events (SAEs) and adverse events leading to discontinuation
(DAEs) from the study.
The study was performed according to Good Clinical
Practice and the Declaration of Helsinki. All local ethics
committees approved the study protocol. All patients gave
their written informed consent for participation.Determination of sample size
With a sample size of 4000 patients in each group of the
main study and a significance level of 5%, the study had
a 90% power to detect a reduction from 10% to 7.9% in the
proportion of patients experiencing a severe asthma exac-
erbation during the 6-month study period. No stratification
was performed related to age at randomisation. No sepa-
rate power calculation was performed for this subgroup
analysis.Statistical analysis
Time to first severe asthma exacerbation was compared
using a Cox proportional hazard model, stratified by
country and with treatment as factor. The total number of
severe exacerbations was compared between the treat-
ments using a Poisson regression model controlling disper-
sion with country and treatment as factors and total time in
study as an offset variable. The comparison between age
groups was calculated using the same methods.The change in ACQ-5 scores, daytime symptoms, night-
time awakenings and lung function was analysed using an
analysis of covariance model with treatment and country as
factors and baseline value as covariate.
Results
Demography
Of the 9695 patients who were enrolled, 8424 were rand-
omised, 8053 were included in the efficacy analysis and
8405 were included in the safety analysis. Baseline demo-
graphic characteristics of the elderly study population and
the reference population are shown in Table 1. There were
1234 patients 65 years (15.3% of the study population) and
11% of the total study population were current smokers
with a mean smoking history of 5.7 pack-years. The mean
FEV1 after bronchodilation in the elderly was 85.6% of their
predicted normal, which was lower than the 91.0% pre-
dicted normal in the younger reference population. The
elderly patients had significantly more asthma symptoms
and were less controlled in their asthma assessed by ACQ-5
score. They also had significantly more comorbidities,
especially ischaemic heart disease and hypertension. There
were no notable important differences in baseline charac-
teristics between elderly patients randomised to treatment
with budesonide/formoterol 1  2 (n Z 618) or 2  2
(n Z 616).
Among the elderly patients, 231 (18.7%) had EOA (58%
females) and 1003 (81.3%) had LOA (69% females). Patients
with EOA had lower baseline post-bronchodilator FEV1
(Table 1). Allergic rhinitis and allergic conjunctivitis were
more prevalent among patients with EOA. Fig. 1 shows the
presence of allergic rhinitis and allergic conjunctivitis in
the entire study population in relation to age. Parameters
reflecting asthma control such as symptoms, night-time
awakenings, use of reliever medication and ACQ-5 scores
were similar in the two groups.
Use of study medication
The mean doses of maintenance and reliever medication
expressed as budesonide doses, in the elderly patients and
in the reference group are shown in Table 2. Both mainte-
nance and reliever usage was very similar in the two age
groups. In both age groups, the total doses were higher in
the 2  2 group and the as-needed doses were lower,
compared to the 1  2 groups.
Exacerbations
During the 6-month study there were a total of 104 elderly
patients with severe exacerbations compared with 379
patients with severe exacerbations in the reference pop-
ulation. The estimated yearly rate of exacerbations among
the elderly was 25.1%, whereas the rate in the reference
population was 15.4% (p < 0.0001).
The difference in time to first severe exacerbation
between the two age groups, regardless of treatment, was
statistically significant, with the risk of the first severe
Table 1 Demographic baseline data in elderly and younger asthmatics, and elderly asthmatics with early- and late-ons asthma.
Characteristics Patients 65
years old
n Z 1234
Patients <65
years old
n Z 6819
p-value Elderly pat ts
with EOA
n Z 231
Elderly patients
with LOA
n Z 1003
p-value
Females, % 67 61 <0.0001 58 69 0.0023
Age, years 71.6 (5.0) 43.5 (12.5) N/A 70.8 (4.5) 71.7 (5.1) 0.0039
Non-smokers, % 77 67 N/A 75 77 0.6168
FEV1, % predicted normal
post-bronchodilation
85.6 (22.7) 91.0 (19.4) <0.0001 81.0 (22.1) 86.6 (22.7) 0.0038
Reversibility, % 6.15 (13.5) 6.11 (12.9) <0.0001 8.44 (12.4) 5.66 (13.6) 0.0159
PEF, % predicted normal
post-bronchodilation
89.8 (28.8) 90.7 (24.0) 0.2958 85.2 (28.1) 90.8 (28.8) 0.0088
ICS dose at entry, mg/day 1114 (595) 1028 (582) 0.0560 1168 (658) 1102 (579) 0.2175
LABA use, % patients 81.7 78.6 0.0016 82.7 77.7 0.0938
SABA use, inhalations/day 1.66 (1.23) 1.49 (1.32) <0.0001 1.76 (1.30) 1.64 (1.20) 0.2040
Days with symptoms/week 4.67 (2.18) 4.34 (2.13) <0.0001 4.60 (2.20) 4.68 (2.20) 0.6214
No. of nights with awakenings/
week
1.24 (1.79) 1.11 (1.59) 0.0147 1.16 (1.80) 1.26 (1.80) 0.4439
ACQ-5 score at baseline 1.92 (1.02) 1.84 (0.99) 0.0127 1.85 (0.99) 1.94 (1.03) 0.2455
No. of exacerbations in past
12 months
1.31 (2.04) 1.47 (2.49) 0.0110 1.26 (1.61) 1.32 (2.12) 0.6536
Comorbidities, % of patients
IHD 10 1.6 <0.0001 11 9 0.3837
Hypertension 43 15 <0.0001 43 43 0.9516
GERD 21 12 <0.0001 20 21 0.8946
Other 32 19 <0.0001 26 33 0.0595
Values shown are means (standard deviation) unless stated otherwise.
ACQ-5 Z five-item Asthma Control Questionnaire; EOA Z early-onset asthma; FEV1 Z forced expiratory volume in 1 s; GERD gastro-oesophageal reflux disease; ICS Z inhaled
corticosteroids; IHD Z ischaemic heart disease; LABA Z long-acting b2-agonist; LOA Z late-onset asthma; N/A Z not applicab PEF Z peak expiratory flow; SABA Z short-acting
b2-agonist.
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Figure 1 Prevalence (and 95% CI) of allergic rhinitis and
allergic conjunctivitis in patients aged 18e96 years versus
reported age when asthma started (n Z 8053).
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Figure 2 Time to first severe exacerbation in elderly
patients (65 years of age) and in the reference group (<65
years of age).
842 J. Haughney et al.exacerbation being increased by 55.3% in the elderly (HR
1.553; 95% confidence interval [CI]: 1.249e1.931;
p < 0.0001) (Fig. 2). The time to first severe asthma
exacerbation in the two age groups is shown in Fig. 3, for
patients treated with 1  2 and 2  2. Although the time to
first severe exacerbation was significantly prolonged in the
remainder of the population studied, the younger age
group, in favour of the 2  2 treatment (HR 0.797; 95% CI:
0.651e0.977; p Z 0.0286), in the elderly population, the
population of interest, there was no difference in time to
first severe exacerbation between the groups treated with
1  2 or 2  2, respectively (HR 0.984; 95% CI: 0.666e1.454;
p Z 0.934).Asthma control questionnaire
The reduction in ACQ-5 total scores in the elderly patients
irrespective of treatment was 0.608 compared with 0.741 in
the reference population. The difference in change of ACQ-
5 between the age groups was 0.133 (p < 0.0001).
Divided by treatment, the changes in ACQ-5 scores both
in the 1  2 and 2  2 groups were similar in the elderly and
in the younger reference population (Table 3). The mean
difference between 1  2 and 2  2 treatments was
significant but small in both the elderly and the reference
group (p Z 0.018 and p < 0.0001, respectively).
Changes in ACQ-5 of more than 0.5 units are illustrated
in Fig. 4. In the elderly patients a total of 49% improved
more than 0.5 units and 9.5% deteriorated. With the 1  2
treatment, 44% of the elderly patients improved and 12%
deteriorated by more than 0.5 units (corresponding figures
in the reference population were 52% and 8%). With 2  2Table 2 Doses of budesonide used during the study.
BUD/FORM maintenance and reliever therapy, mg Patients 
1  2
Maintenance doses 317.3 (23.
As-needed doses 154.4 (175
Total 471.6 (178
Values shown are means (standard deviation).
BUD/FORM Z budesonide/formoterol.treatment 54% improved and 7% deteriorated (56% and 7% in
the reference population).
Changes from baseline in patient-reported
outcomes
Asthma symptoms
The changes in days with asthma symptoms per week from
baseline are shown in Table 3. Small differences were seen
between the age groups and a similar response to the two
randomised treatment groups.
Use of as-needed medication
Before the study all patients used a SABA as reliever
medication. During the study they used budesonide/for-
moterol e the same inhaler as for maintenance therapy.
There was a larger reduction in the usage of as-needed
inhalations in the elderly group (Table 3).
Awakenings
The change in number of night-time awakenings per week
from baseline is shown in Table 3. The difference between
the age groups is small and a similar response to the two
randomised treatments was observed.
Early- versus late-onset asthma
In the elderly, no difference in response to treatment (time
to first severe asthma exacerbation, changes in asthma
symptoms, night-time awakenings, use of reliever medica-
tion and ACQ-5) was observed between the EOA and LOA
groups, in either the 1  2 or the 2  2 group (data not
shown).65 years old Patients <65 years old
2  2 1  2 2  2
1) 635.2 (45.5) 317.6 (17.6) 634.7 (44.3)
.6) 101.7 (146.7) 143.8 (177.5) 102.0 (145.6)
.7) 736.8 (156.5) 461.4 (179.2) 736.5 (152.1)
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Figure 3 Time to first severe exacerbation in elderly
patients (65 years of age) and in the reference group (<65
years of age) treated with budesonide/formoterol 160/4.5 mg
one inhalation twice daily (bid; 1  2) or two inhalations bid
(2  2).
Comparing asthma treatment 843Safety
SAEs were slightly more common in the elderly compared
with the younger reference population. A total of 43 elderly
patients reported an SAE (3.5%) compared with 122 (1.8%) in
the reference population. Five SAE reports among elderly
patients were linked to asthma worsening, compared with 19
such reports in the reference group. Two SAEs in the elderly
group were considered related to treatment, both in the
2  2 group: one case of hypokalaemia, and another of
tachycardia and muscle spasms. One elderly patient died
during the study due to an intracranial haemorrhage which
was considered to be unrelated to the study.
In the elderly population, there were 39 (3.2%) patients
with DAEs compared with 124 patients (1.8%) in the refer-
ence population. In the 1  2 treatment group, there were
13 (2.1%) DAEs among the elderly compared with 57 (1.7%)
in the reference population. In the 2  2 group the corre-
sponding figures were 26 (4.2%) and 67 (2.0%), respectively.
No elderly patients discontinued due to asthma worsening,
but two elderly patients discontinued due to pneumonia.
The percentage of patients using more than eight inha-
lations per day (the highest recommended dose) of bude-
sonide/formoterol (maintenance plus reliever use) was 1.9%
among the elderly and 3.7% in the younger reference group.
Discussion
Our study showed that elderly asthmatics benefited from the
asthma treatment strategy under investigation, budesonide/Table 3 Response to treatment in elderly asthmatics compared
Response to BUD/FORM maintenance and reliever therapy P
1
Change in ACQ-5 
Change in days with asthma symptoms/week 
Change in as-needed inhalationsa 
Change in night-time awakenings/week 
ACQ-5 Z five-item Asthma Control Questionnaire; BUD/FORM Z bude
a Change from SABA doses to budesonide/formoterol doses.formoterolmaintenance and reliever therapy, in a similarway
to the younger reference group. No difference was found in
the elderly populationbetween standardmaintenance (1 2)
andmaximummaintenance treatment (2 2),with respect to
time to the first severe asthma exacerbation. As in the
youngeragegroup,meanACQ-5 scores improved slightlymore
with the higher maintenance dose, but the difference in
change between the treatments was not clinically relevant.
No difference in response to treatment was seen between
elderly patients with EOA or LOA.
This asthma study is one of the largest to include an
elderly population, comprising more than 1200 patients
with ages ranging from 65 to 96 years. The study gives
important information regarding baseline characteristics in
an elderly asthma population with moderate to severe
symptomatic asthma.
There is a problem with underdiagnosis of asthma in the
elderly6,7 as COPD has to be considered as a differential
diagnosis.3 In our study protocol, patients with COPD were
excluded fromenrolment. Smokers were included only if they
had a smoking history of less than 10 pack-years. It is likely,
therefore, that wewere reasonably successful in maintaining
the homogeneity of the respiratory diagnosis. Elderly patients
had a mean lung function within the normal range and they
responded both in reversibility testing and treatment in
a similar way to the younger reference population.
The time to first severe asthma exacerbation was
significantly shorter for elderly asthmatics compared with
the reference population, but we did not find a difference
between the higher maintenance (2  2) treatment and the
standard maintenance treatment (1  2) notwithstanding
the lower treatment load in the 1  2 group. This was
despite elderly patients having more symptoms and lower
lung function at study entry. In our primary paper,21 age
was a poor predictor of requirement for the maximum
maintenance dose; the improvements from baseline in
patient-reported outcomes, i.e. asthma symptoms, night-
time awakenings and use of reliever medication, were of
the same degree in the elderly patients compared with the
rest of the study population. ACQ-5 improved in the elderly
as in the younger population and the improvements with
2  2 were significantly greater than with 1  2, although
numerically small and without clinical importance.
No difference in responses to budesonide/formoterol
maintenance and reliever therapy was seen between
patients with EOA and LOA, either in the 1  2 or in the
2  2 treatment group.
This subgroup analysis showed that elderly patients were
somewhat more symptomatic, used higher doses of ICS andwith the response in patients aged <65 years.
atients 65 years old Patients <65 years old
 2 2  2 1  2 2  2
0.59 0.71 0.69 0.78
1.62 2.21 1.57 2.12
0.71 1.04 0.60 0.86
0.47 0.58 0.44 0.57
sonide/formoterol.
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Figure 4 Clinically important shifts (change of >0.5) from
baseline to treatment in ACQ-5 scores in elderly patients and in
the reference group, and separately for patients treated with
budesonide/formoterol 160/4.5 mg one inhalation bid (1  2) or
two inhalations bid (2  2).
844 J. Haughney et al.more reliever medication, and suffered more often from
comorbidities compared with the younger reference group.
These findings differ from earlier reports on asthma in the
elderly, which state that elderly asthmatics often do not
report symptoms to the same degree as younger patients as
they are “poor perceivers” of symptoms.26,27 A reason for
this discrepancy is perhaps the inclusion criterion of our
study requiring patients to use a reliever inhaler for the
alleviation of symptoms at study entry.
Regarding the usefulness of the budesonide/formoterol
maintenance and reliever therapy in elderly patients, it
was found that the elderly appeared to manage the
regimen equally as well as younger patients in this clinical
trial performed in a real-life setting. The elderly patients
used similar numbers of as-needed inhalations as the
reference group, indicating that the treatment concept was
equally well implemented in the two age groups. This was
also supported by the changes in ACQ-5 scores and the
reductions in days with asthma symptoms per week which
were similar in the elderly compared with the reference
group.
Although statistically significant, no clinically important
differences were found in the shifts in ACQ-5 scores between
the elderly and the younger patients. Almost the same
proportion of elderly patients reported the clinically
important change of 0.5 score units as the younger patients.
In this study, the FEV1 question was excluded from the ACQ
assessment as spirometry was not performed in all centres.
In other large studies the exclusion of FEV1 and use of short-
acting bronchodilators did not alter the validity and
measurement properties of the questionnaire.24,28 In the
absence of spirometry reference values for patients over 75
years old, the EuropeanCommunity of Coal and Steel (ECCS)/
ERS values were used.29 This has probably led to some
overestimation of bronchial obstruction in this age group.
The distribution of patients with allergic rhinitis and/or
allergic conjunctivitis in relation to age at onset of asthma(Fig. 1) clearly demonstrates a higher prevalence in
younger patients. Despite this finding, it is of note that
elderly patients with either EOA or LOA responded equally
well to treatment with budesonide/formoterol; perhaps
distinguishing between these two phenotypes is of minor
importance from a pharmacological view. The slightly lower
lung function among patients with EOA compared with LOA
is in agreement with earlier reports.11,12 However, this
lower baseline lung function was not reflected in EOA
patients experiencing more symptoms. The improvements
in lung function from baseline corresponded to the degree
of reversibility at baseline, i.e. the improvement was
slightly greater in the EOA group.
Although more elderly patients reported SAEs than the
younger patients, this was not linked to asthma worsening
(only 5 out of 43 SAEs were related to asthma). The
proportion of elderly patients using more than the recom-
mended maximum daily dose was lower than in younger
patients. The steroid load during the study, especially in
the 1  2 group, was markedly reduced; this may have
beneficial safety implications, although strong conclusions
cannot be drawn in the absence of a parallel reference
cohort. Use of the lowest effective dose of ICS to control
asthma is even more important in the elderly, where there
are concerns regarding long-term use of high doses of ICS.
We conclude that budesonide/formoterol maintenance
and reliever therapy is a well-tolerated and manageable
treatment concept in elderly asthmatics. The inhaled
steroid load was not higher in the elderly group compared
with the younger reference population. The risk of having
a first exacerbation was greater in the elderly, but no
difference was seen between patients treated with bude-
sonide/formoterol 1  2 and 2  2. ACQ-5 improved equally
in the two age groups. Elderly patients with early- or late-
onset asthma responded equally to treatment. Despite the
absence of difference in exacerbations between the two
maintenance doses and the lack of a reliable reference
value for lung function data in the elderly population, the
level of post-bronchodilator lung function should always be
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